Literature DB >> 23641995

Risk factors for recurrent Mycobacterium ulcerans disease after exclusive surgical treatment in an Australian cohort.

Daniel P O'Brien1, Aaron Walton, Andrew J Hughes, N Deborah Friedman, Anthony McDonald, Peter Callan, Richard Rhadon, Ian Holten, Eugene Athan.   

Abstract

OBJECTIVE: To describe risk factors for recurrence after exclusive surgical treatment of Mycobacterium ulcerans infection. DESIGN, SETTING AND PARTICIPANTS: Prospective observational cohort study of all M. ulcerans cases managed with surgery alone at Barwon Health, a tertiary referral hospital, from 1 January 1998 to 31 December 2011. A random-effects Poisson regression model was used to assess rates and associations of treatment failure. MAIN OUTCOME MEASURES: Rates of treatment failure and rate ratios (RRs) for factors associated with treatment failure.
RESULTS: Of 192 patients with M. ulcerans infection, 50 (26%) had exclusive surgical treatment. Median age was 65.0 2013s (interquartile range [IQR], 45.5-77.7 2013s), and median duration of symptoms was 46 days (IQR, 26-90 days). There were 20 recurrences in 16 patients. For first lesions, the recurrence incidence rate was 41.8 (95% CI, 25.6-68.2) per 100 person-2013s, and median time to recurrence was 50 days (IQR, 30-171 days). Recurrence occurred ≤ 3 cm from the original lesion in 13 cases, and > 3 cm in nine. On univariable analysis, age ≥ 60 2013s (RR 13.84; 95% CI, 2.21-86.68; P < 0.01), distal lesions (RR, 20.43; 95% CI, 1.97-212.22; P < 0.01), positive histological margins (RR, 21.02; 95% CI, 5.51-80.26; P < 0.001), immunosuppression (RR, 17.97; 95% CI, 4.17-77.47; P < 0.01) and duration of symptoms > 75 days (RR, 10.13; 95% CI, 1.76-58.23; P = 0.02) were associated with treatment failure. On multivariable analysis, positive margins (RR, 7.72; 95% CI, 2.71-22.01; P < 0.001) and immunosuppression (RR, 6.45; 95% CI, 2.42-17.20; P = 0.01) remained associated with treatment failure.
CONCLUSIONS: Recurrence rates after exclusive surgical treatment of M. ulcerans disease in an Australian cohort are high, with increased rates associated with immunosuppression or positive histological margins.

Entities:  

Mesh:

Year:  2013        PMID: 23641995     DOI: 10.5694/mja12.11708

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  8 in total

1.  Mycobacterium ulcerans treatment--can antibiotic duration be reduced in selected patients?

Authors:  Raquel Cowan; Eugene Athan; N Deborah Friedman; Andrew J Hughes; Anthony McDonald; Peter Callan; Janet Fyfe; Daniel P O'Brien
Journal:  PLoS Negl Trop Dis       Date:  2015-02-06

2.  Treatment Outcome of Patients with Buruli Ulcer Disease in Togo.

Authors:  Marcus Beissner; Nathalie Arens; Franz Wiedemann; Ebekalisaï Piten; Basile Kobara; Malkin Bauer; Karl-Heinz Herbinger; Kossi Badziklou; Abiba Banla Kere; Thomas Löscher; Jörg Nitschke; Gisela Bretzel
Journal:  PLoS Negl Trop Dis       Date:  2015-10-16

3.  Risk factors for buruli ulcer in Ghana-a case control study in the Suhum-Kraboa-Coaltar and Akuapem South Districts of the eastern region.

Authors:  Ernest Kenu; Kofi Mensah Nyarko; Linda Seefeld; Vincent Ganu; Michael Käser; Margaret Lartey; Benedict Nii Laryea Calys-Tagoe; Kwodwo Koram; Richard Adanu; Oliver Razum; Edwin Afari; Fred N Binka
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

4.  Exposure Risk for Infection and Lack of Human-to-Human Transmission of Mycobacterium ulcerans Disease, Australia.

Authors:  Daniel P O'Brien; James W Wynne; Andrew H Buultjens; Wojtek P Michalski; Timothy P Stinear; N Deborah Friedman; Andrew Hughes; Eugene Athan
Journal:  Emerg Infect Dis       Date:  2017-05       Impact factor: 6.883

5.  Environmental and Behavioral Drivers of Buruli Ulcer Disease in Selected Communities Along the Densu River Basin of Ghana: A Case-Control Study.

Authors:  Samuel Yaw Aboagye; Prince Asare; Isaac Darko Otchere; Eric Koka; George Ekow Mensah; Dzidzo Yirenya-Tawiah; Dorothy Yeboah-Manu
Journal:  Am J Trop Med Hyg       Date:  2017-05       Impact factor: 2.345

Review 6.  Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).

Authors:  Rie R Yotsu; Marty Richardson; Norihisa Ishii
Journal:  Cochrane Database Syst Rev       Date:  2018-08-23

7.  A Genomic Approach to Resolving Relapse versus Reinfection among Four Cases of Buruli Ulcer.

Authors:  Miriam Eddyani; Koen Vandelannoote; Conor J Meehan; Sabin Bhuju; Jessica L Porter; Julia Aguiar; Torsten Seemann; Michael Jarek; Mahavir Singh; Françoise Portaels; Timothy P Stinear; Bouke C de Jong
Journal:  PLoS Negl Trop Dis       Date:  2015-11-30

8.  Low incidence of recurrent Buruli ulcers in treated Australian patients living in an endemic region.

Authors:  James W Wynne; Timothy P Stinear; Eugene Athan; Wojtek P Michalski; Daniel P O'Brien
Journal:  PLoS Negl Trop Dis       Date:  2018-08-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.